Abstract
We studied the adjuvanticity of recombinant Onchocerca volvulus activation associated protein-1 (rOv-ASP-1) for ovalbumin (OVA) in mice. After a single immunization and one boost, rOv-ASP-1 exceeded the efficacy of alum or MPL + TDM adjuvants in terms of end-point total IgG or IgG1 and IgG2a anti-OVA titres. Using the helminth-derived adjuvant, IgG isotype responses to OVA were of a mixed Th1/Th2 profile and spleen cell cytokines exclusively Th1-type. The potent adjuvanticity of rOv-ASP-1 was confirmed in mice vaccinated with a 37-mer peptide from the S protein of SARS-CoV and an HIV-1 gp120-CD4 chimeric polypeptide antigen. Unusually for a helminth product, the rOv-ASP-1 adjuvant augmented not only Th2 but also Th1 responses, the latter property being of potential utility in stimulating anti-viral immune responses.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adjuvants, Immunologic / pharmacology*
-
Animals
-
Antigens, Helminth / administration & dosage*
-
Antigens, Helminth / genetics
-
Antigens, Helminth / immunology
-
Antigens, Helminth / pharmacology
-
HIV-1 / drug effects*
-
HIV-1 / immunology
-
Helminth Proteins / pharmacology*
-
Mice
-
Ovalbumin / chemistry
-
Ovalbumin / immunology
-
Recombinant Proteins / immunology
-
Recombinant Proteins / pharmacology
-
Secretory Vesicles / metabolism
-
Severe acute respiratory syndrome-related coronavirus / drug effects*
-
Severe acute respiratory syndrome-related coronavirus / immunology
-
Th1 Cells / immunology*
-
Th2 Cells / immunology
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / immunology*
Substances
-
Adjuvants, Immunologic
-
Antigens, Helminth
-
Helminth Proteins
-
Ov-ASP-1 protein, Onchocerca volvulus
-
Recombinant Proteins
-
Vaccines, Synthetic
-
Ovalbumin